Login / Signup

Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease.

Nikolas PlevrisPhilip W JenkinsonCher S ChuahMathew LyonsLynne M MerchantRebecca J PattendenIan D ArnottGareth R JonesCharlie W Lees
Published in: Frontline gastroenterology (2019)
In this cohort, trough vedolizumab levels were not associated with clinical, biological or endoscopic outcomes during maintenance therapy.
Keyphrases
  • ultrasound guided
  • ulcerative colitis
  • patients with inflammatory bowel disease
  • stem cells
  • type diabetes
  • metabolic syndrome
  • adipose tissue
  • mesenchymal stem cells
  • glycemic control